Analyst Price Targets — MIRM
Latest News for MIRM
MIRM posts Q4 loss. Revenues jump 50% on strong Livmarli and bile acid drug sales, topping estimates in Q4 2025 and lifting shares.
Although the revenue and EPS for Mirum Pharmaceuticals (MIRM) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.02. This compares to a loss of $0.49 per share a year ago.
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2025 Earnings Call Transcript
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MIRM.
U.S. House Trading
No House trades found for MIRM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.